Tempus AI(TEM)

Material Event filed 2026-05-13

The post From recurrence monitoring to treatment response: MRD data insights across the cancer care continuum appeared first on Tempus .

CHICAGO, May 5, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. Revenue of $348.1 million, up 36.1% year-over-year Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology … Continued The post Tempus Reports First Quarter 2026 Results appeared first on Tempus .

Material Event filed 2026-05-05

Quarterly Report filed 2026-05-05

The path to bringing novel therapies to market is challenged by high attrition rates and the increasing complexity of patient biology. Foundation models offer a new approach to addressing challenges in drug development, particularly when trained on diverse multimodal, de-identified real-world data. In a recent webinar, Tempus leaders Razik Yousfi, SVP and GM of AI … Continued The post Q&A: From proof of concept to clinical deployment: How foundation models are accelerating drug development appeared first on Tempus .

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the company will host an Investor Day on Friday, May 29, 2026. The event will start at 8:00 a.m. CT / 9:00 a.m. ET and will feature Tempus’ leadership team, including, Founder and CEO Eric … Continued The post Tempus to Host Inaugural Investor Day on May 29, 2026 appeared first on Tempus .

As therapies become more targeted, the central challenges of drug development have intensified. Trial protocols are more complex, and finding the right patients for biomarker-driven studies is increasingly difficult, leading to costly enrollment delays and high failure rates.1, 2 At Tempus, we believe the solution is not just a better process, but a fundamentally new … Continued The post Designing smarter trials: A new model for clinical development appeared first on Tempus .

Tempus AI, Inc. (NASDAQ: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence, today announced it has been named to TIME’s 10 Most Influential Health and Life Science Companies of 2026. This inaugural TIME100 Companies: Industry Leaders list, an expansion of the TIME100 Most Influential Companies issue, recognizes the organizations … Continued The post Tempus Named to TIME’s 10 Most Influential Health and Life Science Companies of 2026 appeared first on Tempus .

Objectives Mirvetuximab soravtansine (MIRV), a first-in-class folate receptor alpha (FRα) targeted antibody-drug conjugate (ADC), demonstrated a survival benefit over chemotherapy in the phase III MIRASOL study. To date, no study has evaluated downstream biomarkers that may modulate response which may occur at multiple steps of the ADC pathway. Here, we investigated genomic and transcriptomic alterations … Continued The post Genomic and Transcriptomic Analysis To Uncover Potential Biomarkers of Response and Primary Resistance to Mirvetuximab Soravtansine in Patients With Ovarian Cancer appeared first on Tempus .

Objectives The glycoprotein MUC16 is cleaved to form serum CA125, an established biomarker in endometrial cancer. First-generation MUC16 antibody-drug conjugates (ADCs) were thought to have sub-optimal tumor penetration, in part, because their targeting antibodies were specific for the cleaved portion of CA125 and bound it in serum, creating an antigen sink. Improvements in ADCs—such as … Continued The post High and Stable MUC16 Expression in Endometrial Cancer Highlights Potential for Targeted Antibody-Drug Conjugate Development appeared first on Tempus .